Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial - PubMed
5 hours ago
- #immunotherapy
- #chemoradiotherapy
- #bladder cancer
- Ipilimumab and nivolumab followed by chemoradiotherapy (CRT) tested as bladder-sparing treatment for muscle-invasive bladder cancer (MIBC) in a phase 2 trial.
- The INDIBLADE trial aimed to provide effective bladder-sparing treatment for stage II/III MIBC patients (n=50) using induction immunotherapy followed by CRT.
- Primary endpoint of 2-year bladder-intact event-free survival (BI-EFS) was met at 78%, with 2-year overall survival at 96%.
- Grade 3-4 immune-related adverse events occurred in 24% of patients, while CRT-related adverse events of the same grade occurred in 7%.
- Absence of detectable circulating tumor DNA (ctDNA) after induction immunotherapy was associated with better BI-EFS (HR 8.3, P=0.02).
- The study concludes that induction combination immunotherapy followed by CRT is an effective bladder-sparing treatment for MIBC, with ctDNA serving as a potential monitoring tool.